WEGOVY 1 MG

Wegovy 1 mg – Pre-Filled Semaglutide Pen for Advanced Weight Management Research

Wegovy 1 mg by Novo Nordisk delivers a once-weekly dose of Semaglutide, a GLP-1 receptor agonist used in research involving weight loss, metabolic disorders, and neuroendocrine appetite control. This 1 mg pre-filled pen is the mid-phase step in titration protocols and may also serve as a maintenance dose in longer-term studies.

About Semaglutide and GLP-1 Receptor Activation

Semaglutide mimics the effects of glucagon-like peptide-1 (GLP-1), a natural hormone that regulates insulin secretion, slows gastric emptying, and modulates appetite via hypothalamic signaling. In clinical research, Semaglutide has demonstrated superior outcomes in both glycemic control and body fat reduction. A study published in JAMA highlighted Wegovy's ability to reduce body weight by over 14% in obese participants over 68 weeks.

Research Applications

• Chronic weight loss and fat mass reduction studies
• Appetite suppression and caloric intake modulation
• Insulin resistance and glycemic balance models
• Gut-brain axis and behavioral eating research
• Hormone-based approaches to obesity management

Usage & Dosing in Research Settings

Wegovy 1 mg is administered subcutaneously once per week. It is typically used after the subject has completed 4-week phases at 0.25 mg and 0.5 mg to build tolerance. The 1 mg dose is either sustained as a maintenance protocol or continued until the maximum 2.4 mg dose is reached. Injection sites typically include the thigh, upper arm, or abdomen.

Recommended Research Stacks

To enhance metabolic outcomes or muscle retention, researchers often stack Semaglutide with peptides such as:

• AOD 9604 – GH fragment that promotes fat loss without affecting blood sugar
• CJC-1295 DAC – supports endogenous growth hormone release
• BPC-157 – supports gastrointestinal healing and inflammatory regulation
• GHK-Cu – copper peptide used for insulin sensitivity and body composition support

Safety Profile in Preclinical Studies

Semaglutide's pharmacokinetics include a ~7-day half-life, allowing weekly administration with steady plasma concentration. In preclinical trials, common effects include transient nausea or appetite suppression, typically resolving after the titration phase. Semaglutide is not associated with hepatotoxicity or androgenic effects and is well tolerated in metabolic models.

USA Shipping & Product Details

This Wegovy 1 mg pen is sourced directly from Novo Nordisk and intended for research only. USA domestic orders ship fast and discreetly, with cold-chain handling to preserve product integrity. For flexible dosing, consider our lyophilized Dragon Pharma Semaglutide vial or lower-dose pens like Wegovy 0.5 mg.

Frequently Asked Questions